Evidence-Based Treatments for Addiction and Co-Occurring Eating Disorders Treating substance use disorders alongside eating disorders requires an integrated, whole-person model of care
Retatrutide is a triple-receptor agonist that activates GLP-1, GIP, and glucagon pathways simultaneously, making it the most potent injectable weight loss compound currently in advanced clinical development
Whole foods with minimal added sugar support digestion and provide additional health benefits
PeptIQ was built for exactly this: log your retatrutide doses, set weekly injection reminders, track weight and body metrics, and see your full protocol timeline in one place
Design and synthesis of novel, selective GPR40 AgoPAMs
Taking a smaller dose than what your doctor recommends isnt a good idea Image content: This image is available to view online